



Perspective

Increasing our knowledge base of asthma

John J. Oppenheimer, MD ^{*}; Gailen D. Marshall Jr, MD, PhD [†]^{*} Division of Allergy Immunology, Rutgers-UMDNJ and Pulmonary and Allergy Associates, Summit, New Jersey[†] The University of Mississippi Medical Center, Jackson, Mississippi

ARTICLE INFO

Article history:

Received for publication October 17, 2017.

Accepted for publication October 18, 2017.

Introduction

During the past decade, there has been an explosion in our knowledge of asthma. There are new descriptions of phenotypes, endotypes, and even genotypes. New approaches to management have been and continue to be developed. The realization and characterization of a spectrum of overlap with chronic obstructive pulmonary disease (COPD) in many patients with asthma have been reported in detail and approaches to management of patients with severe asthma continue on the forefront. These and other aspects of asthma are well represented in the more than 200 articles published on asthma since 2015 in the *Annals of Allergy, Asthma and Immunology*. Through the content of these *Annals* articles, clinicians who care for these patients can have a better understanding of the epidemiology, optimization of control measures, and therapy available to effectively treat this illness. In this article we highlight some gains in our understanding of asthma through *Annals* publications. The intent is to provide a synopsis in a single article that will allow the reader to refer to specific *Annals* publications for further information.

Epidemiology

The epidemiology of asthma is important to understand in identifying factors that influence the risk of developing the disease, issues related to management challenges, and identifying distinctive populations as candidates for specific therapeutic approaches. When

considering factors to identify at-risk children, Yamamoto-Hanada et al¹ found that antibiotic use within the first 2 years of life was a risk factor for current asthma in 5-year-old children. Van Meel et al² explored the association between the duration and exclusiveness of breastfeeding and school-age lung function and asthma by comparing 2 to 4 months with longer duration and found that shorter duration and non-exclusivity of breastfeeding were associated with a lower forced expiratory volume in 1 second and forced vital capacity but not with asthma diagnosis at school age (10 years old). Through analysis of the Genes-environments and Admixture in Latino American (GALA II)³ study and the Study of African-Americans, Asthma, Genes, and Environments (SAGE II),⁴ Fishbein et al⁵ demonstrated that pest allergen sensitization was associated with increased risk of asthma exacerbations in urban minority youth. Furthermore, Puerto Rican and other Latino youth sensitized to mouse allergens were more likely to have asthma-related hospitalizations than Mexican youth. Akin et al⁶ found that the simple anthropometric measure of neck circumference was associated with asthma risk in obese children. Lapin et al⁷ demonstrated that prenatal C-reactive protein levels were associated with asthma diagnosis by 3 years of age and wheezing in year 3 in a high-risk urban cohort of mostly Mexican children. They suggested that maternal systemic inflammation might reflect a prenatal environment that could increase offspring susceptibility to develop wheezing and asthma young in life.

Asthma Control

Control of symptoms, exacerbations, and associated morbidities is the fundamental goal of quality asthma care, yet it is clear that, depending on the stakeholder (patient, family, provider, or payer), the meaning of asthma control and how it is measured can vary. There were several articles that explored the issue of achieving and maintaining control and measures of control in asthma. Franklin et al⁸ explored the Predictors of Emergency Department Utilization in Children with Persistent Asthma in an inner-city population and found, after adjustment for socioeconomic status,

Reprints: John J. Oppenheimer, MD, Pulmonary and Allergy Associates, 1 Springfield Avenue, Summit, NJ 07901. E-mail: nalopp22@gmail.com.

Disclosures: Dr Oppenheimer is a consultant for GSK, Teva, DBV, Kaleo, and Church & Dwight; is on the adjudication committees of Quintiles, PRA, and ICON; is associate editor of the *Annals of Allergy, Asthma and Immunology* and *Allergy Watch*; is chief editor of Medscape (pulmonary); and a reviewer for *UpToDate*. Dr Marshall reports grants from Stallergenes, grants from National Institutes of Health, and grants from Sanofi outside the present work. Dr Marshall is editor-in-chief of the *Annals of Allergy, Asthma and Immunology*.

<https://doi.org/10.1016/j.anaai.2017.10.031>

1081-1206/© 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

predictors of emergency department (ED) use in white children included an ED visit in the previous year and sensitization to pets and dust. In contrast, predictors for ED use in African-American children included ED use in the previous year, number of asthma controller medications, routine forced expiratory volume in 1 second less than 80% predicted, blood eosinophil count larger than 4%, and mold allergen sensitization.

Anderson et al⁹ expanded the notion that ideal inhaled corticosteroid (ICS) titration might be dependent on other measurements beyond assessment of symptoms and spirometric results. They found that, although escalation of ICS dosing in persistent asthma led to improvement in pulmonary function and symptoms, a plateau was reached at low to medium doses (equivalent to 200–800 µg of beclomethasone dipropionate). Interestingly, however, ICS dose adjustment resulted in further improvement of inflammatory measurements without a plateau effect. Fractional exhaled nitric oxide (FeNO) values consistently decreased across all ICS dose increases without plateau ($P < .0001$), as did blood eosinophil counts ($P = .03$). Serum eosinophilic cationic protein concentrations decreased only at higher ICS doses ($P = .002$). Airway hyperreactivity (methacholine, histamine, and mannitol) also showed significant improvement across all doses without a plateau effect. An accompanying editorial by Kohn and Oppenheimer¹⁰ reinforced the need for further indicators of asthma control beyond symptoms and spirometry. In addition, it reminds us that no one control measurement is perfect for all patients with asthma.

Building on this observation, a study by Chipps et al¹¹ explored the utility of various tools available to help patients (and families) manage short-term variability in asthma symptoms, focusing on when and how to implement a sustained step up in therapy. They proposed an “asthma yardstick,” which is a comprehensive update on how to develop individualized step-up plans for asthma therapy in patients with less well-controlled or poorly controlled asthma.

Although a pilot study, Phillips et al¹² performed the first prospective cross-sectional study investigating the association between chronic rhinosinusitis symptoms and asthma control measures. They demonstrated a correlation between chronic rhinosinusitis symptom severity and asthma control in their study population. As they noted, further work is needed to determine whether a decrease in chronic rhinosinusitis severity can reliably translate to improvement in asthma control. A study by Sullivan et al¹³ examined the association between asthma control cutoffs and longitudinal changes using the Asthma Control Questionnaire 5 (ACQ-5), with economic outcomes, and provided preliminary economic data on possible control cutoffs for the ACQ-5. Not surprising is that improved asthma control over time appeared to result in significant financial savings. These data provide a rationale for committing additional financial resources to improve control.

Arroyave et al¹⁴ investigated whether differences in morbidity in patients with asthma occur based on their atopic status. They indeed found important differences in asthma morbidity, with those with atopy having more severe asthma. However, there was no difference in asthma control between participants with and without atopy as measured by the Asthma Control Test (ACT). FeNO was a significant marker of inflammation only in participants with atopy, whereas those with high total immunoglobulin E (IgE) in the 2 groups had greater asthma severity and significantly higher FeNO. They suggested that IgE could predict asthma severity and FeNO independent of atopic status.

Asthma Phenotypes

To provide better outcomes for patients with asthma, recent literature has focused on personalized medicine and phenotypic discriminators. There were several recent articles in the *Annals* that addressed this issue, including a review by Desai and Oppenheimer.¹⁵

Recent literature has focused on stratifying asthma based on the airway inflammatory milieu. Most current measures have focused on FeNO and peripheral blood eosinophil counts in clinical practice with sputum and serum periostin assessments in the research setting.

Park et al¹⁶ assessed the utility of serum progranulin levels as a phenotypic biomarker. Progranulin is a protein secreted from the airway epithelium that attenuates the downstream cascade of neutrophilic inflammation. They found that serum progranulin levels had a positive correlation with pulmonary function in patients with asthma and a negative correlation with blood neutrophil counts, with a lower serum progranulin level associated with severe asthma. They pointed out that, although the exact mechanism of progranulin's anti-inflammatory action has not been fully defined, it still could be useful as an indicator of severe asthma with airflow obstruction and that it might have an inhibitory role in neutrophilic airway inflammation.

To further examine phenotypic and endotypic differences in asthma, Tran et al¹⁷ examined the overlap of atopic, eosinophilic, and T-helper cell type 2 high asthma phenotypes in the general population by mining data from the National Health and Nutrition Examination Survey (2005–2006) and found significant overlap among eosinophilic, atopic, and T-helper cell type 2 high asthma phenotypes in a general asthma population.

Beyond classification based on the relative contribution of T-helper cell type 2–based interleukin (IL)–4, IL-5, and IL-13 (so-called T2 high and low), there has been a great deal of discussion about a crossover between asthma and COPD, initially described as “asthma COPD overlap syndrome” and most recently as “asthma-COPD overlap” by the Global Initiative for Asthma.¹⁸ A review by Desai et al¹⁹ reinforced considering this a phenotype of the 2 illnesses when considering treatment options. A retrospective observational study by Liang et al²⁰ found that patients with COPD overlapping with bronchial asthma compared with COPD alone were more likely to be female ($P = .004$) and experienced more severe respiratory exacerbations ($P = .04$) despite being younger ($P = .008$). They also were more likely to have a family history of asthma ($P = .03$), have higher serum allergen-specific IgE ($P = .004$), and have a positive allergic history ($P = .003$). When trying to differentiate these 2 illnesses, Schwingel et al²¹ found that sputum pentraxin 3 (a known neutrophil secretagogue) levels were increased in patients with COPD and had good power to discriminate patients with COPD from patients with asthma and healthy individuals.

Asthma Therapy

The articles published on asthma therapy (>100 since 2015) have been extensive. This article focuses on articles addressing adherence, safety, and new and emerging therapies. Lack of adherence in the use of controller therapy and inappropriate response to loss of asthma control are significant causes of clinical failure of clinical asthma interventions.²² A study by Izadi and Tam²³ evaluated the real-world benefits of patient involvement with an allergist-immunologist and identified impediments for patients in establishing allergy subspecialty care. They found improvement in outcomes in patients who received allergy-immunology follow-up, particularly when the allergists could identify key barriers and prevent future nonadherence. Interestingly, even choosing to go to the ED could be a consequence of some of these barriers.

In a study of inner-city children, Mudd et al²⁴ performed a cluster analysis to correlate caregiver reasons for the decision to use the ED for asthma care as opposed to outpatient care. They identified 3 clusters for decision making: urgency, preference for use of the ED, and issues of access to care. The perception of urgency was the most common reason reported by caregivers (91%) followed by reporting a preference for the ED for care (37%) and reporting issues

of access to care (31%). Lack of access to care was primarily attributable to the inability to schedule a same-day appointment with their primary care practitioner (24%). In the conclusion of their article, they suggested that caregiver home asthma management education and symptom management improved relationships with primary care physicians and improved access and that continuity of primary care could provide a basis for further study and opportunities for intervention and improvement in pediatric asthma care.

Perry et al²⁵ explored the potential for improving asthma outcomes using an asthma action plan smartphone app compared with standard written instructions in a group of adolescents with asthma. They found that, although overall there were no changes in ACT and self-efficacy scores between groups, in subjects with uncontrolled asthma (baseline ACT score ≤ 19) there was an improvement in ACT in the smartphone group (before, 11; after, 20; $P = .04$) compared with no change in the paper group (before, 17; after, 17; $P = .64$). Furthermore, adolescent satisfaction with the application was high, with 100% stating they would recommend the smartphone asthma action plan to a friend. Because this was a small study ($n = 34$), Perry et al suggested the need for a larger-scale study specifically targeting high-risk patients with asthma.

A study by Butz et al²⁶ examined health and social factors associated with the asthma medication ratio (AMR), a measure of guideline-based care and controller medication use, in children with persistent asthma and frequent ED use. In a cohort of largely African-American inner-city children, they found that almost half the subjects had uncontrolled asthma (44%), with 48% receiving non-guideline-based care or low controller medication use based on an AMR smaller than 0.50. The final regression model predicting an AMR larger than 0.50 indicated that children receiving specialty care (odds ratio [OR] 4.87, 95% confidence interval [CI] 2.06–11.50), caregivers reporting minimal worry about medication adverse effects (OR 0.50, 95% CI 0.25–1.00), positive sensitization to ragweed allergen (OR 3.82, 95% CI 1.63–8.96), and negative specific IgE for dust mite (OR 0.33, 95% CI 0.15–0.76) were significantly associated with achieving an AMR larger than 0.50.

Little is known about long-term adherence to biologic agent therapy by patients with severe asthma. Thus, the Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate to Severe Asthma (EXCELS) observational study provided a great opportunity to examine adherence and impediments to adherence to the use of omalizumab. The investigators found that more frequent dosing was associated with a larger number of missed doses, whereas older age (OR per year 1.02, 95% CI 1.01–1.03) and lower pre-bronchodilator percentage of predicted forced expiratory volume in 1 second ($< 76\%$; OR 1.88, 95% CI 1.09–3.24) were independent predictors of good adherence.²⁷

A mini-symposium chaired by Dr Katial provided a data-driven discussion to address gaps in physician understanding related to the efficacy, safety, and bioavailability of ICSs in asthma.^{28–33} This mini-symposium also included discussion regarding the therapeutic role and challenges associated with the use of inhalational devices and patient adherence, with the ultimate goal of improving the care of patients with asthma.^{22,34}

A recent review by Wihelm and Chipps³⁵ discussed the appropriate use of bronchial thermoplasty in patients with severe uncontrolled asthma. Their review summarized published clinical studies that indicated improvement in quality of life and a decrease in overall health care usage in patients receiving bronchial thermoplasty. They stressed that more research is needed to determine what asthma phenotype(s) respond best to this procedure.

Ali et al³⁶ examined the efficacy of a 4-month alfacalcidol (a vitamin D hormone analogue that requires hydroxylation at position 25 to be converted to 1,25-dihydroxyvitamin D) supplementation protocol in adults with asthma. They found improvement in pulmonary function and severity stage in the treated group. This was

evident from the first clinical evaluation after 2 months of treatment. They postulated this efficacy might be secondary to the immunomodulatory and anti-inflammatory effects of active vitamin D. They suggested that larger studies comparing different forms of vitamin D are needed to confirm these results.

Whittington et al³⁷ estimated the cost effectiveness of mepolizumab, a monoclonal antibody directed against IL-5. They demonstrated cost effectiveness for adding mepolizumab to standard of care using a model that evaluated adults with severe uncontrolled asthma and evidence of eosinophilic inflammation with characteristics that mirrored the randomized controlled phase III trial population in an exacerbation end-point trial with 32 weeks of follow-up.³⁸ They concluded that mepolizumab appeared to provide clinical benefits, including lower rates of exacerbation and improved quality of life. However, the estimated cost effectiveness of mepolizumab exceeded commonly used thresholds. They noted that achieving commonly cited value thresholds would require significant discounts from the current mepolizumab list price. However, limiting the use of mepolizumab to responders improved the cost effectiveness toward, but still slightly above, commonly cited value thresholds. They acknowledged that greater gains would be seen with this biologic agent if indirect costs such as absenteeism and attendance had been taken into account in their analysis.

In this review of asthma articles in the *Annals*, it is quite clear that many questions regarding asthma remain; however, you can be sure the *Annals* will continue to be a vehicle for cutting-edge publications in this field. We welcome your comments and suggestions.

References

- Yamamoto-Hanada K, Yang L, Narita M, et al. Influence of antibiotic use in early childhood on asthma and allergic diseases at age 5. *Ann Allergy Asthma Immunol*. 2017;119:54–58.
- van Meel ER, de Jong M, Elbert NJ, et al. Shorter duration and nonexclusivity of breastfeeding were associated with a lower FEV1 and FVC but not asthma at school-age. *Ann Allergy Asthma Immunol*. 2017;119:21–26.
- Burchard EG, Avila PC, Nazario S, et al. Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. *Am J Respir Crit Care Med*. 2004;169:386–392.
- Tsai HJ, Kho JY, Shaikh N, et al. Admixture-matched case-control study: a practical approach for genetic association studies in admixed populations. *Hum Genet*. 2006;118:626–639.
- Fishbein A, Lee T, Cai M, et al. Sensitization to mouse and cockroach allergens and asthma morbidity in urban minority youth. *Ann Allergy Asthma Immunol*. 2016;117:43–49.
- Akin O, Sari E, Arslan M, et al. Association of wider neck circumference and asthma in obese children. *Ann Allergy Asthma Immunol*. 2016;116:514–517.
- Lapin B, Ownby D, Turyk M, et al. Relationship between in utero C-reactive protein levels and asthma in at-risk children. *Ann Allergy Asthma Immunol*. 2015;115:282–287.
- Franklin J, Grunwell J, Bruce A, et al. Predictors of emergency department use in children with persistent asthma in metropolitan Atlanta, Georgia. *Ann Allergy Asthma Immunol*. 2017;119:129–136.
- Anderson W, Short P, Jabbal A, et al. Inhaled corticosteroid dose response in asthma: should we measure inflammation? *Ann Allergy Asthma Immunol*. 2017;118:179–185.
- Kohn G, Oppenheimer J. Control measures in asthma: one size likely does not fit all. *Ann Allergy Asthma Immunol*. 2017;118:123–124.
- Chippis B, Corren J, Israel E, et al. Asthma yardstick: practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. *Ann Allergy Asthma Immunol*. 2017;118:133–142.
- Phillips K, Hoehle L, Caradonna D, et al. Association of severity of chronic rhinosinusitis with degree of comorbid asthma control. *Ann Allergy Asthma Immunol*. 2016;117:651–654.
- Sullivan P, Globe G, Ghushchyan V, et al. Exploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire. *Ann Allergy Asthma Immunol*. 2016;117:251–257.
- Arroyave W, Rabito F, Carlson J, et al. Asthma severity, not asthma control, is worse in atopic compared with nonatopic adolescents with asthma. *Ann Allergy Asthma Immunol*. 2016;116:18–25.
- Desai M, Oppenheimer J. Elucidating asthma phenotypes and endotypes: progress towards personalized medicine. *Ann Allergy Asthma Immunol*. 2016;116:394–401.
- Park S, Hong G, Park S, et al. Serum progranulin as an indicator of neutrophilic airway inflammation and asthma severity. *Ann Allergy Asthma Immunol*. 2016;117:646–650.

- [17] Tran T, Zeiger R, Peters S, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. *Ann Allergy Asthma Immunol*. 2016;116:37–42.
- [18] GINA. 2017 GINA report, global strategy for asthma management and prevention; 2017. <http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/>. Accessed July 15, 2017.
- [19] Desai M, Oppenheimer J, Tashkin D. Asthma-chronic obstructive pulmonary disease overlap syndrome. What we know and what we need to find out. *Ann Allergy Asthma Immunol*. 2017;118:241–245.
- [20] Liang J, Liu L, Fang Q. Clinical characteristics of patients with chronic obstructive pulmonary disease overlapped with bronchial asthma. *Ann Allergy Asthma Immunol*. 2017;118:564–569.
- [21] Schwingel F, Pizzichini E, Kleveston T, et al. Pentraxin 3 sputum levels differ in patients with chronic obstructive pulmonary disease vs asthma. *Ann Allergy Asthma Immunol*. 2015;115:485–489.
- [22] Buckstein D. Patient adherence and effective communication. *Ann Allergy Asthma Immunol*. 2016;117:613–619.
- [23] Izadi N, Tam J. Benefits of subspecialty adherence after asthma hospitalization and patient perceived barriers to care. *Ann Allergy Asthma Immunol*. 2017;118:577–581.
- [24] Mudd S, Ogborn J, Bollinger E, et al. Parental decision making associated with pediatric emergency department use for asthma. *Ann Allergy Asthma Immunol*. 2016;117:490–494.
- [25] Perry T, Marshall A, Berlinski A, et al. Smartphone-based vs paper-based asthma action plans for adolescents. *Ann Allergy Asthma Immunol*. 2017;118:298–303.
- [26] Butz A, Morpew T, Lewis-Land C, et al. Factors associated with poor controller medication use in children with high asthma emergency department use. *Ann Allergy Asthma Immunol*. 2017;118:419–426.
- [27] Janson S, Solari P, Trzaskoma B, et al. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. *Ann Allergy Asthma Immunol*. 2015;114:516–521.
- [28] Katial R. A renewed focus on safety, efficacy, and use of inhaled corticosteroids in asthma. *Ann Allergy Asthma Immunol*. 2016;117:575–576.
- [29] Gerber A. Measuring safety of inhaled corticosteroids in asthma. *Ann Allergy Asthma Immunol*. 2016;117:577–581.
- [30] Covar R. Pivotal efficacy trials of inhaled corticosteroids in asthma. *Ann Allergy Asthma Immunol*. 2016;117:582–588.
- [31] Carr W, Szeffler S. Inhaled corticosteroids: ocular safety and the hypothalamic-pituitary-adrenal axis. *Ann Allergy Asthma Immunol*. 2016;117:589–594.
- [32] Skoner D. Inhaled corticosteroids: effects on growth and bone health. *Ann Allergy Asthma Immunol*. 2016;117:595–600.
- [33] Bensch G. Safety of intranasal corticosteroids. *Ann Allergy Asthma Immunol*. 2016;117:601–605.
- [34] Nelson H. Inhalation devices, delivery systems, and patient technique. *Ann Allergy Asthma Immunol*. 2016;117:606–612.
- [35] Wihelm C, Chipps B. Bronchial thermoplasty: a review of the evidence. *Ann Allergy Asthma Immunol*. 2016;116:92–98.
- [36] Ali A, Selim S, Abbassi M, et al. Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: a randomized trial. *Ann Allergy Asthma Immunol*. 2017;118:557–563.
- [37] Whittington M, McQueen R, Ollendorf D, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. *Ann Allergy Asthma Immunol*. 2017;118:220–225.
- [38] Ortega H, Liu M, Pavord I, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*. 2014;371:1198–1207.